Bioequivalence of two 100 µg/h transdermal fentanyl patches in healthy volunteers

The primary objective of this study is to evaluate the **bioequivalence** of two transdermal therapeutic systems delivering 100 mcg/h **fentanyl** in healthy volunteers. This is clinically relevant as it ensures that the two formulations provide the same therapeutic effect and safety profile, which is crucial for maintaining consistent pain management in patients requiring opioid therapy. No secondary objectives are provided in the available data.

The clinical trial is a **bioequivalence trial** conducted in **healthy volunteers**. The study population includes both male and female participants, with an age range categorized as **3**, which typically corresponds to adults. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants are expected to be in good general health, as the trial is conducted in healthy individuals. No specific lifestyle considerations such as diet, physical activity, or habits have been detailed. The sponsor has not disclosed key inclusion or exclusion criteria for this trial.

The clinical trial is designed to assess the **bioequivalence** of two transdermal therapeutic systems delivering 100 mcg/h fentanyl in healthy volunteers. This is a Phase 2 trial, categorized as a bioequivalence study, and is expected to commence recruitment on April 15, 2025, with an estimated completion date of May 15, 2025. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to receive one of the two transdermal systems, and neither the participants nor the investigators will know which system is being administered, thus maintaining the double-blind nature of the study.

The sequence of study visits begins with an inclusion (screening) visit, where potential participants will be assessed for eligibility based on predefined criteria. This visit is crucial for ensuring that only suitable candidates are enrolled in the trial. Following successful screening, participants will proceed to the baseline visit, where initial measurements and assessments will be conducted. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health and the effects of the transdermal systems. These visits are essential for collecting data on the primary and secondary endpoints of the study.

The end-of-study visit marks the conclusion of the participant's involvement in the trial. During this visit, final assessments will be conducted to gather comprehensive data on the outcomes of the intervention. The expected length of participant involvement is approximately one month, from the screening visit to the end-of-study visit. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the provided data, further details about the experimental and non-experimental treatments, including their administration and monitoring, cannot be elaborated upon. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 2 study, indicating its focus on evaluating the efficacy and side effects of the intervention. The trial is scheduled to commence recruitment on April 15, 2025, with an estimated completion date of May 15, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, Phase 2 trials typically involve measuring clinical outcomes related to the disease being studied. These may include symptom improvement scores, biomarker levels, or disease remission rates, assessed at various timepoints throughout the trial. The methods for measuring and analyzing these parameters are expected to adhere to validated scales and standardized laboratory tests, ensuring the reliability and accuracy of the data collected. The trial's design will likely incorporate tools and instruments appropriate for the specific medical condition under investigation, although these are not specified in the available data.